Innate Pharma SA（IPHA）財務資料IPHAInnate Pharma SA

Innate Pharma SA (IPHA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Collaboration & Licensing Agreements, accounting for 98.5% of total sales, equivalent to €653.00K. Another important revenue stream is Other Activities. Understanding this composition is critical for investors evaluating how IPHA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Innate Pharma SA maintains a gross margin of 66.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -692.10%, while the net margin is -629.95%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IPHA converts its operational activities into shareholder value.

In the context of the broader market, IPHA competes directly with industry leaders such as MENS and CMPX. With a market capitalization of $156.38M, it holds a leading position in the sector. When comparing efficiency, IPHA's gross margin of 66.04% stands against MENS's N/A and CMPX's N/A. Such benchmarking helps identify whether Innate Pharma SA is trading at a premium or discount relative to its financial performance.

The financial performance shows significant losses, with a net income of -€27.6 million in Q1 2026 and a gross margin of -889.87%. Current liabilities exceed current assets, with a current ratio of 1.27, indicating potential liquidity issues.